Jesica Expósito-Escudero

Jesica Expósito-Escudero

Auto-generated profile, based on publicly available information

Jesica Expósito-Escudero

Neuromuscular Unit, Department of Neurology, Hospital Sant Joan de Déu, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2021 in Neurology
Verified
Journal Article
Closed access
PDF file
DBDaniel Natera-De Benito
Daniel Natera-De Benito
AFA. Reghan Foley
A. Reghan Foley
CDCristina Domínguez-González
Cristina Domínguez-González
COCarlos Ortez
Carlos Ortez
MJMinal Jain
Minal Jain
ANAndres Nascimento
Andres Nascimento
Objective To accurately categorize the phenotypes of individuals with collagen VI–related dystrophies (COL6-RDs) during the first years of life to predict long-term motor function and pulmonary function, to provide phenotype-specific anticipatory care, and to improve clinical trial readiness. Methods This retrospective, multicenter, international study analyzed the relationship of long-term motor and pulmonary function with the initial maximal motor ability achieved in individuals with COL6-RD. Results We studied 119 patients with COL6-RD from Spain (n = 54) and the United States (n = 65). The early maximal motor milestones of ability to rise from the floor unassisted and ability to climb 4 steps without holding onto a railing demonstrated reliability in distinguishing between 3 COL6-RD phenotypic subgroups: (1) Ullrich congenital muscular dystrophy, (2) intermediate COL6-RD, and (3) Bethlem myopathy. Long-term motor function and pulmonary function are strongly correlated with the maximal motor ability achieved during the first years of life. Maximal motor capacity can predict other disease-relevant events such as the age at loss of ambulation and the need for the initiation of nocturnal noninvasive ventilation. Conclusion This work proposes a prospective phenotypic classification for COL6-RDs that will enable an accurate prediction of a patient9s COL6-RD phenotype during the first years of life. The ability to establish a patient9s COL6-RD phenotypic classification early will enable a more accurate prognosis of future motor and pulmonary function, thus improving anticipatory clinical care, and it will be instrumental in aiding the design of future clinical trials by allowing early stratification of trial cohorts.

27 September 2024 in European Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
BEBerta Estévez-Arias
Berta Estévez-Arias
LMLeslie Matalonga
Leslie Matalonga
DYDelia Yubero
Delia Yubero
KPKiran Polavarapu
Kiran Polavarapu
ACAnna Codina
Anna Codina
DBDaniel Natera-De Benito
Daniel Natera-De Benito

Verified
Journal Article
Open access
PDF file
CJCristina Jou
Cristina Jou
ANAndres Nascimento
Andres Nascimento
ABAnna Codina Bergada
Anna Codina Bergada
JVJulio Montoya Villarroya
Julio Montoya Villarroya
EGEster Lopez Gallardo
Ester Lopez Gallardo
RARafael Artuch
Rafael Artuch
Thymidine kinase (TK2) deficiency causes mitochondrial DNA depletion syndrome. We aimed to report the clinical, biochemical, genetic, histopathological, and ultrastructural features of a cohort of paediatric patients with TK2 deficiency. Mitochondrial DNA was isolated from muscle biopsies to assess depletions and deletions. The TK2 genes were sequenced using Sanger sequencing from genomic DNA. All muscle biopsies presented ragged red fibres (RRFs), and the prevalence was greater in younger ages, along with an increase in succinate dehydrogenase (SDH) activity and cytochrome c oxidase (COX)-negative fibres. An endomysial inflammatory infiltrate was observed in younger patients and was accompanied by an overexpression of major histocompatibility complex type I (MHC I). The immunofluorescence study for complex I and IV showed a greater number of fibres than those that were visualized by COX staining. In the ultrastructural analysis, we found three major types of mitochondrial alterations, consisting of concentrically arranged lamellar cristae, electrodense granules, and intramitochondrial vacuoles. The pathological features in the muscle showed substantial differences in the youngest patients when compared with those that had a later onset of the disease. Additional ultrastructural features are described in the muscle biopsy, such as sarcomeric de-structuration in the youngest patients with a more severe phenotype.

Verified
Journal Article
Open access
PDF file
ABAnna Codina Bergada
Anna Codina Bergada
MRMónica Roldán
Mónica Roldán
DBDaniel Natera-De Benito
Daniel Natera-De Benito
COCarlos Ortez
Carlos Ortez
RPRobert Planas
Robert Planas
CJCristina Jou
Cristina Jou
Several clinical trials are working on drug development for Duchenne and Becker muscular dystrophy (DMD and BMD) treatment, and, since the expected increase in dystrophin is relatively subtle, high-sensitivity quantification methods are necessary. There is also a need to quantify dystrophin to reach a definitive diagnosis in individuals with mild BMD, and in female carriers. We developed a method for the quantification of dystrophin in DMD and BMD patients using spectral confocal microscopy. It offers the possibility to capture the whole emission spectrum for any antibody, ensuring the selection of the emission peak and allowing the detection of fluorescent emissions of very low intensities. Fluorescence was evaluated first on manually selected regions of interest (ROIs), proving the usefulness of the methodology. Later, ROI selection was automated to make it operator-independent. The proposed methodology correctly classified patients according to their diagnosis, detected even minimal traces of dystrophin, and the results obtained automatically were statistically comparable to the manual ones. Thus, spectral imaging could be implemented to measure dystrophin expression and it could pave the way for detailed analysis of how its expression relates to the clinical course. Studies could be further expanded to better understand the expression of dystrophin-associated protein complexes (DAPCs).

10 December 2024 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
BEBerta Estévez-Arias
Berta Estévez-Arias
LMLeslie Matalonga
Leslie Matalonga
DYDelia Yubero
Delia Yubero
KPKiran Polavarapu
Kiran Polavarapu
ACAnna Codina
Anna Codina
DBDaniel Natera-De Benito
Daniel Natera-De Benito

3 November 2026 in Biocybernetics and Biomedical Engineering
Verified
Journal Article
Open access
RGRoger Gallart-Agut
Roger Gallart-Agut
RPRosa Pàmies-Vilà
Rosa Pàmies-Vilà
AFAlessandra Favata
Alessandra Favata
JEJésica Expósito-Escudero
Jésica Expósito-Escudero
DBDaniel Natera-De Benito
Daniel Natera-De Benito
CTCarme Torras
Carme Torras